期刊
ACTA CYTOLOGICA
卷 63, 期 6, 页码 489-496出版社
KARGER
DOI: 10.1159/000492710
关键词
Non-small cell lung cancer; Lung cancer; Personalized medicine; Liquid biopsy; Circulating tumor DNA; Quantitative polymerase chain reaction; Digital polymerase chain reaction; Next generation sequencing; EGFR
类别
资金
- Department of Public Health, University of Naples Federico II
The identification of non-small cell lung cancer (NSCLC) patients potentially responsive to targeted therapies relies on a number of relevant biomarkers, including EGFR, ALK, ROS-1, and PD-L1. Biomarker identification is most commonly based on surgical sample collection. However, when tissues are difficult to reach or when multiple analyses are necessary to monitor tumor progression and treatment response, liquid biopsy is a valid noninvasive alternative. This analysis, which is preferentially performed on circulating tumor DNA (ctDNA) extracted from plasma samples, has the major advantage of reducing the inherent risks and discomfort of tissue biopsy. However, a major disadvantage is that it yields only a low number of ctDNA targets. Thus, to avoid false-positive and false-negative results, it is important to adopt and validate technologies with high sensitivity and specificity in the pre-analytical phase of sampling. This review succinctly addresses the principal methodologies for analyzing plasma-derived ctDNA in NSCLC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据